← New search
Phenotype profile

ovarian cancer

SaudiVarKB evidence summary derived from retained literature mentions.

115Phenotype mentions
100Publications
50Associated gene records
50Associated variant records

Associated gene records

Co-mentioned in the same publications
GeneIdentifier / contextArticlesMentions
BRCA1HGNC:11002323
BRCA2HGNC:11011818
TP53HGNC:1199866
BRAFHGNC:109744
RAD51DHGNC:982333
PALB2HGNC:2614433
XRCC1HGNC:1282833
PARP1HGNC:27022
CDKN1AHGNC:178422
PTENHGNC:958822
ABCB1HGNC:4022
LDLRHGNC:654722
RAD51CHGNC:982022
MSH6HGNC:732922
FANCIHGNC:2556822
PIK3CAHGNC:897522
CD44HGNC:168122
FANCD2HGNC:358522
BUB1HGNC:114822
BUB1BHGNC:114922
UBE2CHGNC:1593722
BARD1HGNC:95222
SIRT1HGNC:1492911
PAHHGNC:858211
PTTG1HGNC:969011
TNFRSF10DHGNC:1190711
CDK4HGNC:177311
DNMT3BHGNC:297911
CD40HGNC:1191911
TBX4HGNC:1160311
TGHGNC:1176411
SOD1HGNC:1117911
BRD4HGNC:1357511
G6PDHGNC:405711
AGLHGNC:32111
PTGS2HGNC:960511
VEGFAHGNC:1268011
KRASHGNC:640711
ATMHGNC:79511
AKT1HGNC:39111
MALAT1HGNC:2966511
LIG1HGNC:659811
ASPMHGNC:1904811
SCN5AHGNC:1059311
MLH1HGNC:712711
MSH2HGNC:732511
PMS2HGNC:912211
CYP3A5HGNC:263811
RAD51HGNC:981711
ATP8B1HGNC:370611

Associated variant records

Co-mentioned in the same publications
VariantIdentifier / contextArticlesMentions
c.1813C>Tc.1813C>T22
p.L605Fp.L605F22
c.1140dupGc.1140dupG22
c.5095C>Tc.5095C>T22
p.W577Cp.W577C11
G894TG894T11
rs3200401rs320040111
c.1140dupc.1140dup11
p.Arg1699Trpp.Arg1699Trp11
p.Arg1751*p.Arg1751*11
c.3217_3218delc.3217_3218del11
p.Gly1073*p.Gly1073*11
c.5234delc.5234del11
p.Arg2494*p.Arg2494*11
c.643delc.643del11
c.193G>Ac.193G>A11
p.Glu65Leup.Glu65Leu11
rs1061540rs106154011
c.2835-2_2835-1delinsTTc.2835-2_2835-1delinsTT11
c.3425delTc.3425delT11
H132PH132P11
R177CR177C11
R217CR217C11
R230CR230C11
rs1331262028rs133126202811
c.414G>Cc.414G>C11
p.Leu138Phep.Leu138Phe11
c.705G>Tc.705G>T11
p.Lys235Asnp.Lys235Asn11
c.137C>Gc.137C>G11
p.Ser46Cysp.Ser46Cys11
c.620C>Tc.620C>T11
p.Ser207Leup.Ser207Leu11
c.694C>Tc.694C>T11
p.Arg232Terp.Arg232Ter11
c.5407-25T>Ac.5407-25T>A11
c.4136_4137delCTc.4136_4137delCT11
c.1140dupGc.1140dupG11
rs28897672Rs2889767211
rs799917rs79991711
rs4986852rs498685211
c.4136_4137delCTc.4136_4137delCT11
c.5530delCc.5530delC11
c.5266dupCc.5266dupC11
c.68_69delAGc.68_69delAG11
c.4041_4042delAGc.4041_4042delAG11
c.1310_1313delAAGAc.1310_1313delAAGA11
-248G>A-248G>A11
C1236TC1236T11
C3435TC3435T11

Associated population records

Co-mentioned in the same publications
PopulationIdentifier / contextArticlesMentions
Saudi Arabia66
Population recordCohort 1722
Population recordCohort 2722
Population recordCohort 1011
Saudi ArabiaCohort 8811
Saudi Arabia · Riyadh11
Population recordCohort 4711
Saudi Arabia · Jeddah11
Population recordCohort 10011
Population recordCohort 2811
Saudi ArabiaCohort 511
Population recordCohort 1511
Population recordCohort 7011
Population recordCohort 9411
Saudi Arabia · Asir11
Population recordCohort 19211
Saudi Arabia · HailCohort 111
Saudi Arabia · Eastern Province11
Saudi ArabiaCohort 20011
Population recordCohort 73411
Saudi ArabiaCohort 7011
Population recordCohort 19511
Saudi ArabiaCohort 20911
Saudi ArabiaCohort 24011
Saudi ArabiaCohort 90811
Population recordCohort 40711
Saudi ArabiaCohort 5311
Population recordCohort 2,38611
Saudi ArabiaCohort 15911

Supporting publications

100 records
  1. 2026CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research.Current pharmaceutical design1 mentions
  2. 2026Molecular Signature of Cisplatin Resistance in Ovarian Cancer Identifies Therapeutic Opportunities for Re-sensitization.Journal of Cancer1 mentions
  3. 2026Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications.BMC cancer1 mentions
  4. 2026Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets.Biomolecules1 mentions
  5. 2026Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.Journal of neuro-oncology1 mentions
  6. 2026Development of a three-dimensional collagen hydrogel model incorporating laurus nobilis extract-chitosan nanoparticles against ovarian cancer SKOV3 cells.The International journal of artificial organs1 mentions
  7. 2026Machine learning-based DNA microarray analysis for disease detection using the MICRO-AI framework.Science progress1 mentions
  8. 2026Exploring the Prognostic, Mutational and Therapeutic Potential of ANXA2 in Ovarian Cancer via Multi-Omics and In Silico Approach.Biology1 mentions
  9. 2026Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib.Drug design, development and therapy1 mentions
  10. 2026Molecular Characterization of Ovarian Endometriosis in Saudi Arabian Women: Insights into Inflammatory, Autophagic, and Epigenetic Dysregulation.International journal of molecular sciences1 mentions
  11. 2026PPAR-γ agonist Inactivate Cellular Senescence by Inhibiting SIRT1 Signaling to Confer Increased Sensitivity to Olaparib in Ovarian Cancer Cells.Saudi journal of medicine & medical sciences1 mentions
  12. 2026Prevalence of BRCA1 and BRCA2 Germline Mutations in Western Saudi Patients with Epithelial Tubo-Ovarian Carcinoma.Saudi medical journal1 mentions
  13. 2026Applications of artificial intelligence and machine learning models in the prognosis and diagnosis of ovarian cancer.Frontiers in oncology1 mentions
  14. 2026Immune Landscape and Tumour Heterogeneity in Ovarian Cancer: Insights From Single-Cell RNA Sequencing.Journal of cellular and molecular medicine1 mentions
  15. 2025Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer.Biomedical journal1 mentions
  16. 2025A Clinicopathological Study of Surface Epithelial Tumors of the Ovary: A Retrospective Analysis at a Tertiary Care Center in Jeddah, Saudi Arabia.Cureus1 mentions
  17. 2025Unraveling the role of lncRNA in Endometriosis-Associated immune system Dysregulation: Exploring the intricate immunological changes and disrupted signaling pathways.Human immunology1 mentions
  18. 20253D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline.Advanced healthcare materials1 mentions
  19. 2025Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society1 mentions
  20. 2025The Role of Hypoxia-Inducible Factor-1α (HIF-1α) in the Progression of Ovarian Cancer: Perspectives on Female Infertility.Cells1 mentions
  21. 2025Integrative In Silico Analysis to Identify Functional and Structural Impacts of nsSNPs on Programmed Cell Death Protein 1 (PD-1) Protein and UTRs: Potential Biomarkers for Cancer Susceptibility.Genes1 mentions
  22. 2025Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumors.PloS one1 mentions
  23. 2025Bisphenol-A-induced ovarian cancer: Changes in epithelial diversity, apoptosis, antioxidant and anti-inflammatory mechanisms.Reproductive toxicology (Elmsford, N.Y.)1 mentions
  24. 2025Mutational spectrum and profile of breast and ovarian cancer patients in Saudi Arabia's western region: single center experience.Discover oncology1 mentions
  25. 2025A rare presentation of high-grade serous ovarian carcinoma with ulcerating inguinal lymph node metastasis: a case report.Journal of surgical case reports1 mentions
  26. 2025Matrix Metalloproteinases 1 and 3 in Ovarian Cancer: Diagnostic and Prognostic Potential of Genetic Variants and Expression Profiling.Diagnostics (Basel, Switzerland)1 mentions
  27. 2025RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review).International journal of oncology1 mentions
  28. 2025A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy.Food science & nutrition1 mentions
  29. 2025In-silico identification and functional analysis of high-risk oncogenic nsSNPs in the human SDHB gene and their implications for cancer susceptibility.3 Biotech1 mentions
  30. 2025Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation.Bioorganic chemistry1 mentions
  31. 2025P53 Mutation Induces Epithelial-to-Mesenchymal Transition (EMT) Associated with Stem Cell Properties and Tumorigenesis in Fallopian Tube Cells.Cancers1 mentions
  32. 2025Cellular cAMP Content and Mitochondrial Profile Define Different Subtypes of Ovarian Cancer Cells.International journal of molecular sciences1 mentions
  33. 2025Identification of key candidate genes for ovarian cancer using integrated statistical and machine learning approaches.Briefings in bioinformatics1 mentions
  34. 2025Crosstalk between microRNA and oxidative stress in ovarian cancer: diagnosis, pathogenesis and therapeutic resistance.Medical oncology (Northwood, London, England)1 mentions
  35. 2024Identification of Novel Genes and Pathways of Ovarian Cancer Using a Comprehensive Bioinformatic Framework.Applied biochemistry and biotechnology1 mentions
  36. 2024Angio-Long Noncoding RNA MALAT1 (rs3200401) and MIAT (rs1061540) Gene Variants in Ovarian Cancer.Epigenomes1 mentions
  37. 2024Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women.International journal of molecular sciences1 mentions
  38. 2024Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach.Journal of ovarian research1 mentions
  39. 2024Targeting tumour markers in ovarian cancer treatment.Clinica chimica acta; international journal of clinical chemistry1 mentions
  40. 2024From desert flora to cancer therapy: systematic exploration of multi-pathway mechanisms using network pharmacology and molecular modeling approaches.Frontiers in pharmacology1 mentions
  41. 2024The Oncogenic Potential of Human Papillomavirus in Relation to Multiple Types of Cancer in Saudi Arabia: A Systematic Review.Cureus1 mentions
  42. 2024Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.International journal of cancer1 mentions
  43. 2024Stimulator of Interferon Genes Protein (STING) Expression in Cancer Cells: A Tissue Microarray Study Evaluating More than 18,000 Tumors from 139 Different Tumor Entities.Cancers1 mentions
  44. 2024Bisphenol A-induced oxidative stress increases the production of ovarian cancer stem cells in mice.Reproductive toxicology (Elmsford, N.Y.)1 mentions
  45. 2024Effect of novel IL-8 gene mutation on its protein structure and stability among ovarian cancer patients in Saudi Arabia.Bioinformation1 mentions
  46. 2023Pathogenicity of PKCγ Genetic Variants-Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer.Genes1 mentions
  47. 2023Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene.Genes1 mentions
  48. 2023The emerging role of MCPH1/BRIT1 in carcinogenesis.Frontiers in oncology1 mentions
  49. 2023Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases.Frontiers in oncology1 mentions
  50. 2023PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.Scientific reports1 mentions
  51. 2023Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer.Oncology research1 mentions
  52. 2023Identification of novel candidate targets for suppressing ovarian cancer progression through IL-33/ST2 axis components using the system biology approach.Frontiers in molecular biosciences1 mentions
  53. 2023Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.ACS omega1 mentions
  54. 2023Exploring the multi-gene regulatory molecular mechanism of Saudi Arabian flora against epilepsy based on data mining, network pharmacology and docking analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society1 mentions
  55. 2023Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.Journal of surgical oncology1 mentions
  56. 2023Cross talk of tumor protein D52 (TPD52) with KLF9, PKCε, and MicroRNA 223 in ovarian cancer.Journal of ovarian research1 mentions
  57. 2023Exploring the role of lncrna neat1 knockdown in regulating apoptosis across multiple cancer types: A review.Pathology, research and practice1 mentions
  58. 2023Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.Biomedicines1 mentions
  59. 2023Maximal clique centrality and bottleneck genes as novel biomarkers in ovarian cancer.Biotechnology & genetic engineering reviews1 mentions
  60. 2022Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.Mini reviews in medicinal chemistry1 mentions
  61. 2022Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.BMC cancer1 mentions
  62. 2022Low-Grade Serous Carcinoma of the Ovary: The Current Status.Diagnostics (Basel, Switzerland)1 mentions
  63. 2022Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach.Life (Basel, Switzerland)1 mentions
  64. 2022Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants.Genes1 mentions
  65. 2022The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.Cancers1 mentions
  66. 2022Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.Cancer genetics1 mentions
  67. 2022Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers.NPJ precision oncology1 mentions
  68. 2022Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism.Frontiers in oncology1 mentions
  69. 2022The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity.Diagnostics (Basel, Switzerland)1 mentions
  70. 2021Screening for PIK3CA mutations among Saudi women with ovarian cancer.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology1 mentions
  71. 2021Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.Oncogene1 mentions
  72. 2021FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.Cancers1 mentions
  73. 2021Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.JCI insight1 mentions
  74. 2021Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.Journal of molecular medicine (Berlin, Germany)1 mentions
  75. 2021The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families.Cancers1 mentions
  76. 2021Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers.Theranostics1 mentions
  77. 2021A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.Genome medicine1 mentions
  78. 2021Leptin Protein Expression and Promoter Methylation in Ovarian Cancer: A Strong Prognostic Value with Theranostic Promises.International journal of molecular sciences1 mentions
  79. 2021Predicting Diagnostic Potential of Cathepsin in Epithelial Ovarian Cancer: A Design Validated by Computational, Biophysical and Electrochemical Data.Biomolecules1 mentions
  80. 2020Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.Genomics1 mentions
  81. 2020Molecular Evaluation of PROGINS Mutation in Progesterone Receptor Gene and Determination of its Frequency, Distribution Pattern and Association with Breast Cancer Susceptibility in Saudi Arabia.Endocrine, metabolic & immune disorders drug targets1 mentions
  82. 2020Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.British journal of cancer1 mentions
  83. 2020Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.Future oncology (London, England)1 mentions
  84. 2020Design and encapsulation of anticancer dual HSP27 and HER2 inhibitor into low density lipoprotein to target ovarian cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society1 mentions
  85. 2020MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer.Frontiers in genetics1 mentions
  86. 2020Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.Genes1 mentions
  87. 2020Tissue-based long non-coding RNAs "PVT1, TUG1 and MEG3" signature predicts Cisplatin resistance in ovarian Cancer.Genomics1 mentions
  88. 2020BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.Scientific reports1 mentions
  89. 2019Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review.Gene1 mentions
  90. 2019Novel Associations between BRCA1 Variants C.181 T>G (Rs28897672) and Ovarian Crisk in Saudi Females.Journal of medical biochemistry1 mentions
  91. 2019Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.Human mutation1 mentions
  92. 2019Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.BMC cancer1 mentions
  93. 2019Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment.Journal of controlled release : official journal of the Controlled Release Society1 mentions
  94. 2019Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.Molecules (Basel, Switzerland)1 mentions
  95. 2019miRNA-21 inhibition suppresses the human epithelial ovarian cancer by targeting PTEN signal pathway.Saudi journal of biological sciences1 mentions
  96. 2018High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.Breast cancer research and treatment1 mentions
  97. 2018Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus.Oncotarget1 mentions
  98. 2016Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico1 mentions
  99. 2016Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.Human genomics1 mentions
  100. 2016Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.Journal of ovarian research1 mentions